Literature DB >> 18617903

Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy.

E Rosen, A Rubowitz, J R Ferencz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617903     DOI: 10.1038/eye.2008.218

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  8 in total

1.  Idiopathic choroidal neovascularisation in pregnancy: treatment options and a successful outcome.

Authors:  Samantha Roshani De Silva; Farhat Bibi; Kuan Sim; Mandeep Singh Bindra
Journal:  BMJ Case Rep       Date:  2016-07-19

2.  Intravitreal bevacizumab injection in unrecognised early pregnancy.

Authors:  L Sullivan; S P Kelly; A Glenn; C P R Williams; M McKibbin
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

Review 3.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 4.  Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature.

Authors:  Silvio Polizzi; Vinit B Mahajan
Journal:  J Ocul Pharmacol Ther       Date:  2015-08-24       Impact factor: 2.671

5.  Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy.

Authors:  Farzan Kianersi; Heshmatollah Ghanbari; Zahra Naderi Beni; Afsaneh Naderi Beni
Journal:  Invest New Drugs       Date:  2016-06-02       Impact factor: 3.850

Review 6.  Pregnancy and the Eye.

Authors:  Nursal Melda Yenerel; Raciha Beril Küçümen
Journal:  Turk J Ophthalmol       Date:  2015-10-05

Review 7.  Ocular changes during pregnancy.

Authors:  Mohammad Naderan
Journal:  J Curr Ophthalmol       Date:  2018-01-03

Review 8.  Diabetic retinopathy in pregnancy - A review.

Authors:  Priya R Chandrasekaran; V G Madanagopalan; Raja Narayanan
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.